Zoledronic acid: Its use in the treatment of breast cancer

Clinical Medicine Insights: Therapeutics

Volumn 2, Issue , 2010, Pages 913-926

  Luís, Inês Vaz ^a,b   Casimiro, Sandra ^b   Ribeiro, Joana ^a,b   Costa, Luís ^a,b  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b UNIVERSITY OF LISBON   (Portugal)

Author keywords

Bone; Breast cancer; Cancer treatment induced bone loss; Metastases; Skeletal related event; Zoledronic acid

Indexed keywords

ANASTROZOLE; CLODRONIC ACID; DENOSUMAB; DOXORUBICIN; GERANYLTRANSFERASE; GOSERELIN; IBANDRONIC ACID; LETROZOLE; MEVALONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; PACLITAXEL; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; BONE DENSITY; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOPROPHYLAXIS; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PREFERENCE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EVENT FREE SURVIVAL; FRACTURE; HEART ATRIUM FIBRILLATION; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY FAILURE; MULTIPLE CYCLE TREATMENT; NEPHROTIC SYNDROME; NEPHROTOXICITY; OSTEOCLAST; OSTEOLYSIS; OVERALL SURVIVAL; PATIENT COMPLIANCE; PATIENT PREFERENCE; POSTMENOPAUSE; PREMENOPAUSE; REVIEW; STROKE;

EID: 78650793004     PISSN: 1179559X     EISSN: 1179559X     Source Type: Journal    
DOI: 10.4137/CMT.S2353     Document Type: Review

References (121)

1. Garcia M, Jemal A, Ward EM, et al. Global Cancer Facts and Figure 2007. Atlanta, GA: American Cancer Society; 2007.
2. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165-176.
3. Lipton A, Theriault R, Hortobagyi G, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000 Mar;88(5):1082-1090.
4. Saad F. Bisphosphonates can prevent skeletal complications of malignant bone disease from prostate cancer and renal cell carcinoma. 2007;(6):683-688.
5. Hei Y, Saad F, Coleman R, Chen Y. Fractures negatively affect survival in patients with bone metastases from breast cancer. Breast Cancer Res Treat. 2005:94. Abstract 6036.
6. Costa L, Major PP. Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol. 2009 Mar;6(3):163-174.
7. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008 Mar;19(3):420-432.
8. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002 Aug;2(8):584-593.
9. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone. 1999 Jul;25(1):97-106.
10. Amin D, Cornell SA, Gustafson SK, et al. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. Journal of Lipid Research. 1992 Nov;33(11):1657-1663.
11. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. The Journal of Pharmacology and Experimental Therapeutics. 2001 Feb;296(2):235-242.
12. van beek E, Lowik C, van der Pluijm G, Papapoulos S. The role of gera-nylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res. 1999 May;14(5):722-729.
13. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998 Apr;13(4):581-589.
14. Alakangas A, Selander K, Mulari M, et al. Alendronate disturbs vesicular traffcking in osteoclasts. Calcifed Tissue International. 2002 Jan;70(1):40-47.
15. Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone. 2001 May;28(5):465-473.
16. Monkkonen H, Auriola S, Lehenkari P, et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bispho-sphonates. British Journal of Pharmacology. 2006 Feb;147(4):437-445.
17. Neville-Webbe HL, Coleman RE. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer. 2010 May;46(7):1211-1222.
18. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000 Jun 1;60(11):2949-2954.
19. van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest. 1996 Aug 1;98(3):698-705.
20. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bis-phosphonate compound zoledronic acid. The Journal of Pharmacology and Experimental Therapeutics. 2002 Sep;302(3):1055-1061.
21. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifcations of circulating angiogenetic factors in cancer patients. Clin Cancer Res. 2002 May;8(5):1080-1084.
22. Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2003 Aug 1;9(8):2893-2897.
23. Sato K, Kimura S, Segawa H, et al. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immuno-therapy. International Journal of Cancer. 2005 Aug 10;116(1):94-99.
24. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000 Jul 15;96(2): 384-392.
25. Wilhelm M, Kunzmann V, Eckstein S, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood. 2003 Jul 1; 102(1):200-206.
26. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001 Apr 20;84(8): 1126-1134.
27. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphospho-nates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000 Apr;82(8):1459-1468.
28. Coleman RE. Future directions in the treatment and prevention of bone metastases. Am J Clin Oncol. 2002;25:32-38.
29. Green JR. Bisphosphonates: preclinical review. Oncologist. 2004;9 Suppl 4: 3-13.
30. Santini D, Vespasiani Gentilucci U, Vincenzi B. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol. 2003;14:1468-1476.
31. Magnetto S, Boissier S, Delmas PD, Clezardin P. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. International Journal of Cancer. 1999 Oct 8;83(2):263-269.
32. Woodward JK, Neville-Webbe HL, Coleman RE, Holen I. Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro. Anti-Cancer Drugs. 2005 Sep;16(8):845-854.
33. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. International Journal of Cancer. 2005 Jan 20;113(3):364-371.
34. Neville-Webbe HL, Evans CA, Coleman RE, Holen I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol. 2006;27(2):92-103.
35. Saeki T, Sasaki Y, Itoh K, Igarashi T, Minami H. Zoledronate: phase I and pharmacokinetics/pharmacodynamics study in cancer patients. Bone. 2000; 26:41.
36. Berenson JR, Ravera C, M P, Deckert F. Population pharmacokinetics (PK) of Zometa. Paper presented at: 36th Annual Meeting of the American Society of Clinical Oncology 2000; New Orleans.
37. Lin J. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996 Feb;18(2):75-85.
38. Russell R, Watts N, Ebetino F, Rogers M. Mechanisms of action of biphos-phonates: Similarities and differences and their potential infuence on clinical effcacy. Osteoporos Int. 1998;19:733-759.
39. Coxon F, Thompson K, Roelofs A, Ebetino F, Rogers M. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone. 2008 May;42(5):848-860.
40. Kohno N, Aogi K, Minami H. Zoledronic acid signifcantly reduces skeletal complications compared with placebo in Japonese women with bone metastases from breast cancer: a randomised, placebo-controlled trial. J Clin Oncol. 2005;23:3314-3321.
41. Rosen LS, Gordon D, Kaminski M. Long-term effcacy and safety of zole-dronic acid compared to pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomised, double blind, multicenter, comparative trial. Cancer. 2003;98:1735-1744.
42. Rosen LS, Gordon D, Kaminski M. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or oste-olytic lesions of multiple myeloma: a phase III, double blind, comparative trial. Cancer J. 2001;7:377-3787.
43. Rosen LS, Gordon D, Dugan WJ. Zoledronic acid is superior to pamidronate in the treatment of bone metastases in breast cancer patinets with at least one osteolytic lesion. Cancer. 2004;100:36-43.
44. Body J, Cook R, Costa L, et al. Patients with bone metastases from solid tumours and poor prognostic features may gain survival benefts from zoledronic acid. Paper presented at: 10th International Conference Cancer Induced Bone Disease 2010; Sheffeld.
45. Stopeck A, BodY J, Fujiwara Y, et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. European Journal of Cancer Supplements. 2009;7(3):2.
46. van Poznak C, Sauter N. Clinical management of osteoporosis in women with a history of breast carcinoma. Cancer. 2005 Aug;104(3):443-456.
47. Gralow J, Biermann J, Farooki A, et al. NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw. 2009 Jun;7 Suppl 3:1-32; quiz S33-5.
48. van Poznak C, Morris P, D'Andrea G. Changes in BMD of postmenopausal women who are not receiving adjuvant endocrine therapy for breast cancer (BCA). Cancer Res. 2009;6924:559s. Abstract 1066.
49. Chien A, Goss P. Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol. 2006 Nov;24(33):5305-5312.
50. Hadji P, Body J, Aapro M, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol. 2008 Aug;19(8): 1407-1416.
51. Raisz L. Clinical practice. Screening for osteoporosis. N Engl J Med. 2005 Jul;353(2):164-171.
52. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008 Mar 1;26(7):1051-1057.
53. Hillner B, Ingle J, Chlebowski R, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003 Nov;21(21):4042-4057.
54. Powles T, Hickish T, Kanis J, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996 Jan;14(1):78-84.
55. Shapiro C, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol. 2001 Jul;19(14):3306-3311.
56. Powles T, McCloskey E, Paterson A, et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst. 1998 May;90(9):704-708.
57. Saarto T, Blomqvist C, Välimäki M, Mäkelä P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fuo-rouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol. 1997 Apr;15(4):1341-1347.
58. Delmas P, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate risedronate prevents bone loss in women with artifcial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol. 1997 Mar;15(3):955-962.
59. Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol. 2006 Feb;24(4):675-680.
60. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007 Mar;25(7):820-828.
61. Sverrisdóttir A, Fornander T, Jacobsson H, von Schoultz E, Rutqvist L. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol. 2004 Sep;22(18):3694-3699.
62. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008 Sep;9(9):840-849.
63. Hershman D, McMahon D, Crew K, et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2008 Oct;26(29):4739-4745.
64. Hershman D, McMahon D, Crew K, et al. Prevention of bone loss by zole-dronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab. 2010 Feb;95(2):559-566.
65. Shapiro C, Manola J, Leboff M. Effect of zoledronic acid on bone mineral density in premenopausal women who devlop ovarian failure due to adjuvant chemotherapy: First results from CALGB trial 79809. J Clin Oncol. 2008;26(9s).
66. Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clinical Breast Cancer. 2009 May;9(2): 77-85.
67. Brufsky A, Harker W, Beck J, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007 Mar;25(7):829-836.
68. Bundred N, Campbell I, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer. 2008 Mar;112(5):1001-1010.
69. Eidtmann H, Bundred N, Deboer R, et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. Paper presented at: CTRC-AACR San Antonio Breast Cancer Symposium 2008; San Antonio, USA.
70. Schenk N, Liombart A, Frassoladti A. The E-ZO-FAST trial: zoledronic acid (ZA) effectively inhibits aromatase inhibitors associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole (LET). Eur J Cancer. 2007;5:186-187. Abstract 2008.
71. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letro-zole: 36-month results of the ZO-FAST Study. Ann Oncol. 2010 Nov;21(11): 2188-2194.
72. Coleman RE, Bundred N, de Boer R, et al. Impact of zoledronic acid in post-menopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST (in press). CTRC-AACR San Antonio Breast Cancer Symposium. Vol San Antonio, USA: Cancer Research; 2009.
73. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zole-dronic acid in premenopausal breast cancer. N Engl J Med. 2009 Feb 12; 360(7):679-691.
74. Gnant M, Mlineritsch B, Stoeger H, et al. 62-month follow-up of ABCSG-12. Adjuvant endocrine therapy, alone or in combination with zoledronic acid, in premenopausal patients with endocrine-responsive early breast cancer. Paper presented at: 10th International Conference Cancer-Induced Bone Disease 2010; Sheffeld.
75. Mauri D, Valachis A, Polyzos N, et al. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials. J Natl Compr Canc Netw. 2010 Mar;8(3): 279-286.
76. Coleman R, Winter M, Cameron D, et al. The effects of adding zole-dronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer. 2010 Mar;102(7):1099-1105.
77. Adami S, Bhalla A, Dorizzi R, et al. The acute-phase response after bispho-sphonate administration. Calcifed Tissue International. 1987 Dec;41(6): 326-331.
78. Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003 Jul;64(1):281-289.
79. Chang J, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med. 2003 Oct;349(17):1676-1679. discussion 1676-9.
80. Jones S, Dolan G, Lengyel K, Myers B. Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zole-dronic acid infusions. Br J Haematol. 2002 Nov;119(2):576-577.
81. Markowitz G, Fine P, Stack J, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 200 Jul 3;64(1):281-289.
82. Dunstan C, Felsenberg D, Seibel M. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol. 2007 Jan;4(1):42-55.
83. Peter R, Mishra V, Fraser W. Severe hypocalcaemia after being given intravenous bisphosphonate. BMJ. 2004 Feb;328(7435):335-336.
84. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws AAoOaMS. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007 Mar;65(3):369-376.
85. Edwards BJ, Gounder M, McKoy JM, et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteone-crosis of the jaw. Lancet Oncol. 2008 Dec;9(12):1166-1172.
86. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphospho-nates. N Engl J Med. 2005 Jul 7;353(1):99-102. discussion 199-102.
87. Sanna G, Preda L, Bruschini R, et al. Bisphosphonates and jaw osteonecro-sis in patients with advanced breast cancer. Ann Oncol. 2006 Oct;17(10): 1512-1516.
88. Palaska P, Cartsos V, Zavras A. Bisphosphonates and time to osteonecrosis development. Oncologist. 2009 Nov;14(11):1154-1166.
89. Coleman R, Woodward E, Brown J, et al. Safety of Zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE-BIG 01-04) for women with stage II/III breast cancer. Paper presented at: 10th International Conference Cancer-Induced Bone Disease 2010; Sheffeld.
90. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006 Feb;24(6):945-952.
91. Durie B, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005 Jul;353(1):99-102. discussion 199-102.
92. Saussez S, Javadian R, Hupin C, et al. Bisphosphonate-related osteone-crosis of the jaw and its associated risk factors: a Belgian case series. Laryngoscope. 2009 Feb;119(2):323-329.
93. Edwards B, Gounder M, McKoy J, et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol. 2008 Dec;9(12):1166-1172.
94. Bertoldo F, Santini D, Lo Cascio V. Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. Nat Clin Pract Oncol. 2007 Dec;4(12): 711-721.
95. Raje N, Woo S, Hande K, et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008 Apr;14(8):2387-2395.
96. van den Wyngaert T, Huizing M, Fossion E, Vermorken J. Bisphosphonates in oncology: rising stars or fallen heroes. Oncologist. 2009 Feb;14(2): 181-191.
97. Pozzi S, Vallet S, Mukherjee S, et al. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res. 2009 Sep;15(18):5829-5839.
98. Reid I, Bolland M, Grey A. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone. 2007 Sep;41(3):318-320.
99. Estilo C, van Poznak C, Wiliams T, et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist. 2008 Aug;13(8):911-920.
100. Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med. 2006 Mar;35(3):155-160.
101. Naik N, Russo T. Bisphosphonate-related osteonecrosis of the jaw: the role of actinomyces. Clin Infect Dis. 2009 Dec;49(11):1729-1732.
102. Drake M, Clarke B, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008 Sep;83(9):1032-1045.
103. Ripamonti C, Maniezzo M, Campa T, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bispho-sphonates. The experience of the National Cancer Institute of Milan. Ann Oncol. 2009 Jan;20(1):137-145.
104. Grey A. Teriparatide for Bone Loss in the Jaw. N Engl J Med. 2010 Oct 16.
105. Lau AN, Adachi JD. Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy. J Rheumatol. 2009 Aug;36(8): 1835-1837.
106. Cheung A, Seeman E. Teriparatide Therapy for Alendronate-Associated Osteonecrosis of the Jaw. N Engl J Med. 2010 Oct 16.
107. Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc. 2009 Jul;84(7):632-637; quiz 638.
108. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008 Mar 20;358(12):1304-1306.
109. Kwek EB, Koh JS, Howe TS. More on atypical fractures of the femoral diaphysis. N Engl J Med. 2008 Jul 17;359(3):316-317. author reply 317-8.
110. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009 Jun;24(6):1095-1102.
111. Whyte MP. Atypical femoral fractures, bisphosphonates, and adult hypo-phosphatasia. J Bone Miner Res. 2009 Jun;24(6):1132-1134.
112. Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf. 2009;32(9):775-785.
113. Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009 Aug;20(8):1353-1362.
114. Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010 May 13; 362(19):1761-1771.
115. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007 May 3; 356(18):1809-1822.
116. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007 Nov 1; 357(18):1799-1809.
117. FDA: Update of safety review follow-up to the 2007 Oct 1, early communication about the ongoing safety review of bisphosphonates Error! Hyperlink reference not valid.
118. Wilkinson GS, Baillargeon J, Kuo YF, Freeman JL, Goodwin JS. Atrial Fibrillation and Stroke Associated With Intravenous Bisphosphonate Therapy in Older Patients With Cancer. J Clin Oncol. 2010 Oct 12.
119. Chern B, Joseph D, Joshua D, et al. Bisphosphonate infusions: patient preference, safety and clinic use. Support Care Cancer. 2004 Jun;12(6):463-466.
120. Mangiapane S, Hoer A, H G. Higher persistency with iv biphosphonates in patients with bone metastasis. ASCO Meeting Abstracts. 2006;24:18623.
121. Gol D. Poor persistency with oral bisphosphonates in cancer patients with bone metastasis. Proc Am Soc Clin Oncol. 2004:(Abstr 8221).